

Kazuko Nagase

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5882324/publications.pdf>

Version: 2024-02-01

8
papers

147
citations

1307594
7
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

167
citing authors

#	ARTICLE	IF	CITATIONS
1	Complications of Leukocytapheresis. <i>Therapeutic Apheresis and Dialysis</i> , 1998, 2, 120-124.	0.6	38
2	Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1808-1815.	2.8	38
3	Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant. <i>Therapeutic Apheresis and Dialysis</i> , 2004, 8, 45-51.	0.9	17
4	A Suppository Chinese Medicine (Xilei-san) for Refractory Ulcerative Proctitis: A Pilot Clinical Trial. <i>Digestion</i> , 2007, 75, 146-147.	2.3	16
5	Xilei San Ameliorates Experimental Colitis in Rats by Selectively Degrading Proinflammatory Mediators and Promoting Mucosal Repair. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-10.	1.2	15
6	Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 367-373.	0.9	12
7	Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. <i>Cytotherapy</i> , 2014, 16, 821-825.	0.7	8
8	Questionnaire Based Assessment of Patients' Acceptability of Leukocytapheresis for the Treatment of Inflammatory Bowel Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 490-497.	0.9	3